Our Advisory Board.
Mark Swaim, MD, PhD
Mark is editor-in-chief and founder of BioPub, a small-cap biotech investing situations analysis website with a global following. He graduated summa cum laude from University of North Carolina with a chemistry and was a rare junior-year inductee into Phi Beta Kappa.
In the NIH-sponsored Medical Scientist Training Program at Duke University, he earned an MD with junior election to Alpha Omega Alpha and a PhD in biochemistry and cell biology with special distinction.
He trained in categorical internal medicine at Duke, completed post-doctoral work in distintegrins at National Taiwan University (Taipei), and returned to Duke for research and clinical fellowships in gastroenterology and transplant hepatology.
After serving on the faculties of Duke, where he was awarded the medical center’s highes teaching honor, and later University of Texas MD Anderson Cancer Center (Houston), where he was elected to the faculty senate, and UT Health Science Center in Houston, he established an independent freestanding hepatology clinic and clinical research institute, leading clinical trials for a large number of pharma companies and speaking nationally on interferon therapeutics for virus hepatitis as a key opinion leader for many years.
He authored more than three dozen peer-reviewed publications and chapters, over 100 abstracts, and was elected Fellow of the American College of Physicians in 2002.
With an impressive record of success in biotech investing and analysis, and the growing success of BioPub, he decided to devote all energies to guiding biotech investors, analyzing investing situations, and serving as a consultant to the biotech industry.
Tony is one of the most experienced Investment Bankers in Canada in the healthcare and biotechnology industry sectors.
In 1987, Tony was instrumental in the creation and funding of MDS Capital Corp., Canada’s largest venture capital fund dedicated to the life sciences, now known as Lumira Capital.
Most recently, Tony was an investment banker in the healthcare and biotechnology industries with Dominick Capital Corp.
Dr. Eleanor Fish
TDr. Fish is an accomplished scientist with focus on interferon activity against variety of viruses including Covid-19, SARA, Ebola and Zika. During the 2003 outbreak of SARS in Toronto, Dr. Fish initiated studies to investigate the therapeutic potential of interferon in SARS patients. Encouraging results have directed her group’s efforts toward examining interferon activity against a number of emerging infectious diseases.
Dr. Fish is a Professor, Department of Immunology, University of Toronto, Associate Chair, International Initiatives & Collaborations, University of Toronto and Emerita Scientist, Toronto General Hospital Research Institute, University Health Network. She received a B.Sc. from the University of Manchester, U.K., an M.Phil. from King’s College, University of London, U.K. and a Ph.D. from the Institute of Medical Sciences at the University of Toronto, Canada. Dr. Fish is a Fellow of the American Academy of Microbiologists and a Fellow of the African Academy of Sciences. Dr. Fish has received many international awards acknowledging her scientific achievements and has published more than 170 peer reviewed scientific papers in international journals.
She is the principle author of the most recent paper published on Friday May 15, 2020 in Frontiers of Immunology titled “Interferon-α2b Treatment for COVID-19”.